Global Sickle Cell Anemia Drug Market

Sickle Cell Anemia Drug Comprehensive Study by Type (Antibiotics, Hydroxyurea, Pain-relieving medications, Others), Mode of Administration (Oral, Intravenous), Disease Type (Sickle cell anemia, Sickle beta thalassemia, Sickle hemoglobin c disease), Distribution Channel (Retail pharmacies, Hospital pharmacies, Online pharmacies) Players and Region - Global Market Outlook to 2024

Sickle Cell Anemia Drug Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Sickle Cell Anemia Drug Market Overview:
Sickle cell anemia is also known as sickle cell disease, a group of inherited red blood cell disorder. Normal red blood cells are round. In sickle cell anemia, some red blood cells become deformed, so they look like sickles or crescent moons. A few common symptoms of sickle cell disease is the infection, pain, and fatigue.

Market Drivers
  • Growing Geriatric Population in Major Economies
  • Increasing Healthcare Spending and Demand for Drug Therapy


Restraints
  • Stringent Government Rules and Regulation

Opportunities
  • R&D and Product Innovation
  • Potential Growth From Emerging Countries

Challenges
  • Availability of Substitute


Competitive Landscape:
The global Sickle Cell Anemia Drug market is highly concentrated by numerous key players. The Intensity of rivalry appears to be high in this market as competitors are numerous and the drugs are undifferentiated. Major companies in this market are constantly working towards introducing innovative products and lowering production costs in order to enhance profitability.
Some of the key players profiled in the report are Alnylam Pharmaceuticals, Inc. (United States), Pfizer Inc. (United States), Novartis AG (Switzerland), Eli Lilly and Company (United States), AstraZeneca Plc. (United Kingdom), Baxter International Inc. (United States), Emmaus Life Sciences, Inc. (United States), Sangamo Therapeutics, Inc. (United States), Bluebird bio, Inc. (United States), Global Blood Therapeutics Inc. (United States), Bristol-Myers Squibb Company (United States), Acceleron Pharma, Inc. (United States) and Arena Pharmaceuticals, Inc. (United States). Analyst at AdvanceMarketAnalytics see United States Players to retain maximum share of Global Sickle Cell Anemia Drug market by 2024. Considering Market by Mode of Administration, the sub-segment i.e. Oral will boost the Sickle Cell Anemia Drug market. Considering Market by Disease Type, the sub-segment i.e. Sickle cell anemia will boost the Sickle Cell Anemia Drug market. Considering Market by Distribution Channel, the sub-segment i.e. Retail pharmacies will boost the Sickle Cell Anemia Drug market.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Sickle Cell Anemia Drug market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Sickle Cell Anemia Drug market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Sickle Cell Anemia Drug Distributors/Traders/Wholesalers, Sickle Cell Anemia Drug Subcomponent Manufacturers, Industry Association, Downstream Vendors and Other.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Antibiotics
  • Hydroxyurea
  • Pain-relieving medications
  • Others
By Mode of Administration
  • Oral
  • Intravenous

By Disease Type
  • Sickle cell anemia
  • Sickle beta thalassemia
  • Sickle hemoglobin c disease

By Distribution Channel
  • Retail pharmacies
  • Hospital pharmacies
  • Online pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Geriatric Population in Major Economies
      • 3.2.2. Increasing Healthcare Spending and Demand for Drug Therapy
    • 3.3. Market Challenges
      • 3.3.1. Availability of Substitute
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Sickle Cell Anemia Drug, by Type, Mode of Administration, Disease Type, Distribution Channel and Region (value, volume and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Sickle Cell Anemia Drug (Value)
      • 5.2.1. Global Sickle Cell Anemia Drug by: Type (Value)
        • 5.2.1.1. Antibiotics
        • 5.2.1.2. Hydroxyurea
        • 5.2.1.3. Pain-relieving medications
        • 5.2.1.4. Others
      • 5.2.2. Global Sickle Cell Anemia Drug by: Mode of Administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Intravenous
      • 5.2.3. Global Sickle Cell Anemia Drug by: Disease Type (Value)
        • 5.2.3.1. Sickle cell anemia
        • 5.2.3.2. Sickle beta thalassemia
        • 5.2.3.3. Sickle hemoglobin c disease
      • 5.2.4. Global Sickle Cell Anemia Drug by: Distribution Channel (Value)
        • 5.2.4.1. Retail pharmacies
        • 5.2.4.2. Hospital pharmacies
        • 5.2.4.3. Online pharmacies
      • 5.2.5. Global Sickle Cell Anemia Drug Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Sickle Cell Anemia Drug (Volume)
      • 5.3.1. Global Sickle Cell Anemia Drug by: Type (Volume)
        • 5.3.1.1. Antibiotics
        • 5.3.1.2. Hydroxyurea
        • 5.3.1.3. Pain-relieving medications
        • 5.3.1.4. Others
      • 5.3.2. Global Sickle Cell Anemia Drug by: Mode of Administration (Volume)
        • 5.3.2.1. Oral
        • 5.3.2.2. Intravenous
      • 5.3.3. Global Sickle Cell Anemia Drug by: Disease Type (Volume)
        • 5.3.3.1. Sickle cell anemia
        • 5.3.3.2. Sickle beta thalassemia
        • 5.3.3.3. Sickle hemoglobin c disease
      • 5.3.4. Global Sickle Cell Anemia Drug by: Distribution Channel (Volume)
        • 5.3.4.1. Retail pharmacies
        • 5.3.4.2. Hospital pharmacies
        • 5.3.4.3. Online pharmacies
      • 5.3.5. Global Sickle Cell Anemia Drug Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Sickle Cell Anemia Drug (Price)
      • 5.4.1. Global Sickle Cell Anemia Drug by: Type (Price)
  • 6. Sickle Cell Anemia Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Alnylam Pharmaceuticals, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eli Lilly and Company (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AstraZeneca Plc. (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Baxter International Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Emmaus Life Sciences, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sangamo Therapeutics, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bluebird bio, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Global Blood Therapeutics Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Bristol-Myers Squibb Company (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Acceleron Pharma, Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Arena Pharmaceuticals, Inc. (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Sickle Cell Anemia Drug Sale, by Type, Mode of Administration, Disease Type, Distribution Channel and Region (value, volume and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Sickle Cell Anemia Drug (Value)
      • 7.2.1. Global Sickle Cell Anemia Drug by: Type (Value)
        • 7.2.1.1. Antibiotics
        • 7.2.1.2. Hydroxyurea
        • 7.2.1.3. Pain-relieving medications
        • 7.2.1.4. Others
      • 7.2.2. Global Sickle Cell Anemia Drug by: Mode of Administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Intravenous
      • 7.2.3. Global Sickle Cell Anemia Drug by: Disease Type (Value)
        • 7.2.3.1. Sickle cell anemia
        • 7.2.3.2. Sickle beta thalassemia
        • 7.2.3.3. Sickle hemoglobin c disease
      • 7.2.4. Global Sickle Cell Anemia Drug by: Distribution Channel (Value)
        • 7.2.4.1. Retail pharmacies
        • 7.2.4.2. Hospital pharmacies
        • 7.2.4.3. Online pharmacies
      • 7.2.5. Global Sickle Cell Anemia Drug Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Sickle Cell Anemia Drug (Volume)
      • 7.3.1. Global Sickle Cell Anemia Drug by: Type (Volume)
        • 7.3.1.1. Antibiotics
        • 7.3.1.2. Hydroxyurea
        • 7.3.1.3. Pain-relieving medications
        • 7.3.1.4. Others
      • 7.3.2. Global Sickle Cell Anemia Drug by: Mode of Administration (Volume)
        • 7.3.2.1. Oral
        • 7.3.2.2. Intravenous
      • 7.3.3. Global Sickle Cell Anemia Drug by: Disease Type (Volume)
        • 7.3.3.1. Sickle cell anemia
        • 7.3.3.2. Sickle beta thalassemia
        • 7.3.3.3. Sickle hemoglobin c disease
      • 7.3.4. Global Sickle Cell Anemia Drug by: Distribution Channel (Volume)
        • 7.3.4.1. Retail pharmacies
        • 7.3.4.2. Hospital pharmacies
        • 7.3.4.3. Online pharmacies
      • 7.3.5. Global Sickle Cell Anemia Drug Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Sickle Cell Anemia Drug (Price)
      • 7.4.1. Global Sickle Cell Anemia Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Sickle Cell Anemia Drug: by Type(USD Million)
  • Table 2. Sickle Cell Anemia Drug Antibiotics , by Region USD Million (2013-2018)
  • Table 3. Sickle Cell Anemia Drug Hydroxyurea , by Region USD Million (2013-2018)
  • Table 4. Sickle Cell Anemia Drug Pain-relieving medications , by Region USD Million (2013-2018)
  • Table 5. Sickle Cell Anemia Drug Others , by Region USD Million (2013-2018)
  • Table 6. Sickle Cell Anemia Drug: by Mode of Administration(USD Million)
  • Table 7. Sickle Cell Anemia Drug Oral , by Region USD Million (2013-2018)
  • Table 8. Sickle Cell Anemia Drug Intravenous , by Region USD Million (2013-2018)
  • Table 9. Sickle Cell Anemia Drug: by Disease Type(USD Million)
  • Table 10. Sickle Cell Anemia Drug Sickle cell anemia , by Region USD Million (2013-2018)
  • Table 11. Sickle Cell Anemia Drug Sickle beta thalassemia , by Region USD Million (2013-2018)
  • Table 12. Sickle Cell Anemia Drug Sickle hemoglobin c disease , by Region USD Million (2013-2018)
  • Table 13. Sickle Cell Anemia Drug: by Distribution Channel(USD Million)
  • Table 14. Sickle Cell Anemia Drug Retail pharmacies , by Region USD Million (2013-2018)
  • Table 15. Sickle Cell Anemia Drug Hospital pharmacies , by Region USD Million (2013-2018)
  • Table 16. Sickle Cell Anemia Drug Online pharmacies , by Region USD Million (2013-2018)
  • Table 17. South America Sickle Cell Anemia Drug, by Country USD Million (2013-2018)
  • Table 18. South America Sickle Cell Anemia Drug, by Type USD Million (2013-2018)
  • Table 19. South America Sickle Cell Anemia Drug, by Mode of Administration USD Million (2013-2018)
  • Table 20. South America Sickle Cell Anemia Drug, by Disease Type USD Million (2013-2018)
  • Table 21. South America Sickle Cell Anemia Drug, by Distribution Channel USD Million (2013-2018)
  • Table 22. Brazil Sickle Cell Anemia Drug, by Type USD Million (2013-2018)
  • Table 23. Brazil Sickle Cell Anemia Drug, by Mode of Administration USD Million (2013-2018)
  • Table 24. Brazil Sickle Cell Anemia Drug, by Disease Type USD Million (2013-2018)
  • Table 25. Brazil Sickle Cell Anemia Drug, by Distribution Channel USD Million (2013-2018)
  • Table 26. Argentina Sickle Cell Anemia Drug, by Type USD Million (2013-2018)
  • Table 27. Argentina Sickle Cell Anemia Drug, by Mode of Administration USD Million (2013-2018)
  • Table 28. Argentina Sickle Cell Anemia Drug, by Disease Type USD Million (2013-2018)
  • Table 29. Argentina Sickle Cell Anemia Drug, by Distribution Channel USD Million (2013-2018)
  • Table 30. Rest of South America Sickle Cell Anemia Drug, by Type USD Million (2013-2018)
  • Table 31. Rest of South America Sickle Cell Anemia Drug, by Mode of Administration USD Million (2013-2018)
  • Table 32. Rest of South America Sickle Cell Anemia Drug, by Disease Type USD Million (2013-2018)
  • Table 33. Rest of South America Sickle Cell Anemia Drug, by Distribution Channel USD Million (2013-2018)
  • Table 34. Asia Pacific Sickle Cell Anemia Drug, by Country USD Million (2013-2018)
  • Table 35. Asia Pacific Sickle Cell Anemia Drug, by Type USD Million (2013-2018)
  • Table 36. Asia Pacific Sickle Cell Anemia Drug, by Mode of Administration USD Million (2013-2018)
  • Table 37. Asia Pacific Sickle Cell Anemia Drug, by Disease Type USD Million (2013-2018)
  • Table 38. Asia Pacific Sickle Cell Anemia Drug, by Distribution Channel USD Million (2013-2018)
  • Table 39. China Sickle Cell Anemia Drug, by Type USD Million (2013-2018)
  • Table 40. China Sickle Cell Anemia Drug, by Mode of Administration USD Million (2013-2018)
  • Table 41. China Sickle Cell Anemia Drug, by Disease Type USD Million (2013-2018)
  • Table 42. China Sickle Cell Anemia Drug, by Distribution Channel USD Million (2013-2018)
  • Table 43. Japan Sickle Cell Anemia Drug, by Type USD Million (2013-2018)
  • Table 44. Japan Sickle Cell Anemia Drug, by Mode of Administration USD Million (2013-2018)
  • Table 45. Japan Sickle Cell Anemia Drug, by Disease Type USD Million (2013-2018)
  • Table 46. Japan Sickle Cell Anemia Drug, by Distribution Channel USD Million (2013-2018)
  • Table 47. India Sickle Cell Anemia Drug, by Type USD Million (2013-2018)
  • Table 48. India Sickle Cell Anemia Drug, by Mode of Administration USD Million (2013-2018)
  • Table 49. India Sickle Cell Anemia Drug, by Disease Type USD Million (2013-2018)
  • Table 50. India Sickle Cell Anemia Drug, by Distribution Channel USD Million (2013-2018)
  • Table 51. South Korea Sickle Cell Anemia Drug, by Type USD Million (2013-2018)
  • Table 52. South Korea Sickle Cell Anemia Drug, by Mode of Administration USD Million (2013-2018)
  • Table 53. South Korea Sickle Cell Anemia Drug, by Disease Type USD Million (2013-2018)
  • Table 54. South Korea Sickle Cell Anemia Drug, by Distribution Channel USD Million (2013-2018)
  • Table 55. Taiwan Sickle Cell Anemia Drug, by Type USD Million (2013-2018)
  • Table 56. Taiwan Sickle Cell Anemia Drug, by Mode of Administration USD Million (2013-2018)
  • Table 57. Taiwan Sickle Cell Anemia Drug, by Disease Type USD Million (2013-2018)
  • Table 58. Taiwan Sickle Cell Anemia Drug, by Distribution Channel USD Million (2013-2018)
  • Table 59. Australia Sickle Cell Anemia Drug, by Type USD Million (2013-2018)
  • Table 60. Australia Sickle Cell Anemia Drug, by Mode of Administration USD Million (2013-2018)
  • Table 61. Australia Sickle Cell Anemia Drug, by Disease Type USD Million (2013-2018)
  • Table 62. Australia Sickle Cell Anemia Drug, by Distribution Channel USD Million (2013-2018)
  • Table 63. Rest of Asia-Pacific Sickle Cell Anemia Drug, by Type USD Million (2013-2018)
  • Table 64. Rest of Asia-Pacific Sickle Cell Anemia Drug, by Mode of Administration USD Million (2013-2018)
  • Table 65. Rest of Asia-Pacific Sickle Cell Anemia Drug, by Disease Type USD Million (2013-2018)
  • Table 66. Rest of Asia-Pacific Sickle Cell Anemia Drug, by Distribution Channel USD Million (2013-2018)
  • Table 67. Europe Sickle Cell Anemia Drug, by Country USD Million (2013-2018)
  • Table 68. Europe Sickle Cell Anemia Drug, by Type USD Million (2013-2018)
  • Table 69. Europe Sickle Cell Anemia Drug, by Mode of Administration USD Million (2013-2018)
  • Table 70. Europe Sickle Cell Anemia Drug, by Disease Type USD Million (2013-2018)
  • Table 71. Europe Sickle Cell Anemia Drug, by Distribution Channel USD Million (2013-2018)
  • Table 72. Germany Sickle Cell Anemia Drug, by Type USD Million (2013-2018)
  • Table 73. Germany Sickle Cell Anemia Drug, by Mode of Administration USD Million (2013-2018)
  • Table 74. Germany Sickle Cell Anemia Drug, by Disease Type USD Million (2013-2018)
  • Table 75. Germany Sickle Cell Anemia Drug, by Distribution Channel USD Million (2013-2018)
  • Table 76. France Sickle Cell Anemia Drug, by Type USD Million (2013-2018)
  • Table 77. France Sickle Cell Anemia Drug, by Mode of Administration USD Million (2013-2018)
  • Table 78. France Sickle Cell Anemia Drug, by Disease Type USD Million (2013-2018)
  • Table 79. France Sickle Cell Anemia Drug, by Distribution Channel USD Million (2013-2018)
  • Table 80. Italy Sickle Cell Anemia Drug, by Type USD Million (2013-2018)
  • Table 81. Italy Sickle Cell Anemia Drug, by Mode of Administration USD Million (2013-2018)
  • Table 82. Italy Sickle Cell Anemia Drug, by Disease Type USD Million (2013-2018)
  • Table 83. Italy Sickle Cell Anemia Drug, by Distribution Channel USD Million (2013-2018)
  • Table 84. United Kingdom Sickle Cell Anemia Drug, by Type USD Million (2013-2018)
  • Table 85. United Kingdom Sickle Cell Anemia Drug, by Mode of Administration USD Million (2013-2018)
  • Table 86. United Kingdom Sickle Cell Anemia Drug, by Disease Type USD Million (2013-2018)
  • Table 87. United Kingdom Sickle Cell Anemia Drug, by Distribution Channel USD Million (2013-2018)
  • Table 88. Netherlands Sickle Cell Anemia Drug, by Type USD Million (2013-2018)
  • Table 89. Netherlands Sickle Cell Anemia Drug, by Mode of Administration USD Million (2013-2018)
  • Table 90. Netherlands Sickle Cell Anemia Drug, by Disease Type USD Million (2013-2018)
  • Table 91. Netherlands Sickle Cell Anemia Drug, by Distribution Channel USD Million (2013-2018)
  • Table 92. Rest of Europe Sickle Cell Anemia Drug, by Type USD Million (2013-2018)
  • Table 93. Rest of Europe Sickle Cell Anemia Drug, by Mode of Administration USD Million (2013-2018)
  • Table 94. Rest of Europe Sickle Cell Anemia Drug, by Disease Type USD Million (2013-2018)
  • Table 95. Rest of Europe Sickle Cell Anemia Drug, by Distribution Channel USD Million (2013-2018)
  • Table 96. MEA Sickle Cell Anemia Drug, by Country USD Million (2013-2018)
  • Table 97. MEA Sickle Cell Anemia Drug, by Type USD Million (2013-2018)
  • Table 98. MEA Sickle Cell Anemia Drug, by Mode of Administration USD Million (2013-2018)
  • Table 99. MEA Sickle Cell Anemia Drug, by Disease Type USD Million (2013-2018)
  • Table 100. MEA Sickle Cell Anemia Drug, by Distribution Channel USD Million (2013-2018)
  • Table 101. Middle East Sickle Cell Anemia Drug, by Type USD Million (2013-2018)
  • Table 102. Middle East Sickle Cell Anemia Drug, by Mode of Administration USD Million (2013-2018)
  • Table 103. Middle East Sickle Cell Anemia Drug, by Disease Type USD Million (2013-2018)
  • Table 104. Middle East Sickle Cell Anemia Drug, by Distribution Channel USD Million (2013-2018)
  • Table 105. Africa Sickle Cell Anemia Drug, by Type USD Million (2013-2018)
  • Table 106. Africa Sickle Cell Anemia Drug, by Mode of Administration USD Million (2013-2018)
  • Table 107. Africa Sickle Cell Anemia Drug, by Disease Type USD Million (2013-2018)
  • Table 108. Africa Sickle Cell Anemia Drug, by Distribution Channel USD Million (2013-2018)
  • Table 109. North America Sickle Cell Anemia Drug, by Country USD Million (2013-2018)
  • Table 110. North America Sickle Cell Anemia Drug, by Type USD Million (2013-2018)
  • Table 111. North America Sickle Cell Anemia Drug, by Mode of Administration USD Million (2013-2018)
  • Table 112. North America Sickle Cell Anemia Drug, by Disease Type USD Million (2013-2018)
  • Table 113. North America Sickle Cell Anemia Drug, by Distribution Channel USD Million (2013-2018)
  • Table 114. United States Sickle Cell Anemia Drug, by Type USD Million (2013-2018)
  • Table 115. United States Sickle Cell Anemia Drug, by Mode of Administration USD Million (2013-2018)
  • Table 116. United States Sickle Cell Anemia Drug, by Disease Type USD Million (2013-2018)
  • Table 117. United States Sickle Cell Anemia Drug, by Distribution Channel USD Million (2013-2018)
  • Table 118. Canada Sickle Cell Anemia Drug, by Type USD Million (2013-2018)
  • Table 119. Canada Sickle Cell Anemia Drug, by Mode of Administration USD Million (2013-2018)
  • Table 120. Canada Sickle Cell Anemia Drug, by Disease Type USD Million (2013-2018)
  • Table 121. Canada Sickle Cell Anemia Drug, by Distribution Channel USD Million (2013-2018)
  • Table 122. Mexico Sickle Cell Anemia Drug, by Type USD Million (2013-2018)
  • Table 123. Mexico Sickle Cell Anemia Drug, by Mode of Administration USD Million (2013-2018)
  • Table 124. Mexico Sickle Cell Anemia Drug, by Disease Type USD Million (2013-2018)
  • Table 125. Mexico Sickle Cell Anemia Drug, by Distribution Channel USD Million (2013-2018)
  • Table 126. Sickle Cell Anemia Drug Sales: by Type(K Unit)
  • Table 127. Sickle Cell Anemia Drug Sales Antibiotics , by Region K Unit (2013-2018)
  • Table 128. Sickle Cell Anemia Drug Sales Hydroxyurea , by Region K Unit (2013-2018)
  • Table 129. Sickle Cell Anemia Drug Sales Pain-relieving medications , by Region K Unit (2013-2018)
  • Table 130. Sickle Cell Anemia Drug Sales Others , by Region K Unit (2013-2018)
  • Table 131. Sickle Cell Anemia Drug Sales: by Mode of Administration(K Unit)
  • Table 132. Sickle Cell Anemia Drug Sales Oral , by Region K Unit (2013-2018)
  • Table 133. Sickle Cell Anemia Drug Sales Intravenous , by Region K Unit (2013-2018)
  • Table 134. Sickle Cell Anemia Drug Sales: by Disease Type(K Unit)
  • Table 135. Sickle Cell Anemia Drug Sales Sickle cell anemia , by Region K Unit (2013-2018)
  • Table 136. Sickle Cell Anemia Drug Sales Sickle beta thalassemia , by Region K Unit (2013-2018)
  • Table 137. Sickle Cell Anemia Drug Sales Sickle hemoglobin c disease , by Region K Unit (2013-2018)
  • Table 138. Sickle Cell Anemia Drug Sales: by Distribution Channel(K Unit)
  • Table 139. Sickle Cell Anemia Drug Sales Retail pharmacies , by Region K Unit (2013-2018)
  • Table 140. Sickle Cell Anemia Drug Sales Hospital pharmacies , by Region K Unit (2013-2018)
  • Table 141. Sickle Cell Anemia Drug Sales Online pharmacies , by Region K Unit (2013-2018)
  • Table 142. South America Sickle Cell Anemia Drug Sales, by Country K Unit (2013-2018)
  • Table 143. South America Sickle Cell Anemia Drug Sales, by Type K Unit (2013-2018)
  • Table 144. South America Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2013-2018)
  • Table 145. South America Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2013-2018)
  • Table 146. South America Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2013-2018)
  • Table 147. Brazil Sickle Cell Anemia Drug Sales, by Type K Unit (2013-2018)
  • Table 148. Brazil Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2013-2018)
  • Table 149. Brazil Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2013-2018)
  • Table 150. Brazil Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2013-2018)
  • Table 151. Argentina Sickle Cell Anemia Drug Sales, by Type K Unit (2013-2018)
  • Table 152. Argentina Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2013-2018)
  • Table 153. Argentina Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2013-2018)
  • Table 154. Argentina Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2013-2018)
  • Table 155. Rest of South America Sickle Cell Anemia Drug Sales, by Type K Unit (2013-2018)
  • Table 156. Rest of South America Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2013-2018)
  • Table 157. Rest of South America Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2013-2018)
  • Table 158. Rest of South America Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2013-2018)
  • Table 159. Asia Pacific Sickle Cell Anemia Drug Sales, by Country K Unit (2013-2018)
  • Table 160. Asia Pacific Sickle Cell Anemia Drug Sales, by Type K Unit (2013-2018)
  • Table 161. Asia Pacific Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2013-2018)
  • Table 162. Asia Pacific Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2013-2018)
  • Table 163. Asia Pacific Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2013-2018)
  • Table 164. China Sickle Cell Anemia Drug Sales, by Type K Unit (2013-2018)
  • Table 165. China Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2013-2018)
  • Table 166. China Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2013-2018)
  • Table 167. China Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2013-2018)
  • Table 168. Japan Sickle Cell Anemia Drug Sales, by Type K Unit (2013-2018)
  • Table 169. Japan Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2013-2018)
  • Table 170. Japan Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2013-2018)
  • Table 171. Japan Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2013-2018)
  • Table 172. India Sickle Cell Anemia Drug Sales, by Type K Unit (2013-2018)
  • Table 173. India Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2013-2018)
  • Table 174. India Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2013-2018)
  • Table 175. India Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2013-2018)
  • Table 176. South Korea Sickle Cell Anemia Drug Sales, by Type K Unit (2013-2018)
  • Table 177. South Korea Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2013-2018)
  • Table 178. South Korea Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2013-2018)
  • Table 179. South Korea Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2013-2018)
  • Table 180. Taiwan Sickle Cell Anemia Drug Sales, by Type K Unit (2013-2018)
  • Table 181. Taiwan Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2013-2018)
  • Table 182. Taiwan Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2013-2018)
  • Table 183. Taiwan Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2013-2018)
  • Table 184. Australia Sickle Cell Anemia Drug Sales, by Type K Unit (2013-2018)
  • Table 185. Australia Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2013-2018)
  • Table 186. Australia Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2013-2018)
  • Table 187. Australia Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2013-2018)
  • Table 188. Rest of Asia-Pacific Sickle Cell Anemia Drug Sales, by Type K Unit (2013-2018)
  • Table 189. Rest of Asia-Pacific Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2013-2018)
  • Table 190. Rest of Asia-Pacific Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2013-2018)
  • Table 191. Rest of Asia-Pacific Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2013-2018)
  • Table 192. Europe Sickle Cell Anemia Drug Sales, by Country K Unit (2013-2018)
  • Table 193. Europe Sickle Cell Anemia Drug Sales, by Type K Unit (2013-2018)
  • Table 194. Europe Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2013-2018)
  • Table 195. Europe Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2013-2018)
  • Table 196. Europe Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2013-2018)
  • Table 197. Germany Sickle Cell Anemia Drug Sales, by Type K Unit (2013-2018)
  • Table 198. Germany Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2013-2018)
  • Table 199. Germany Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2013-2018)
  • Table 200. Germany Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2013-2018)
  • Table 201. France Sickle Cell Anemia Drug Sales, by Type K Unit (2013-2018)
  • Table 202. France Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2013-2018)
  • Table 203. France Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2013-2018)
  • Table 204. France Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2013-2018)
  • Table 205. Italy Sickle Cell Anemia Drug Sales, by Type K Unit (2013-2018)
  • Table 206. Italy Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2013-2018)
  • Table 207. Italy Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2013-2018)
  • Table 208. Italy Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2013-2018)
  • Table 209. United Kingdom Sickle Cell Anemia Drug Sales, by Type K Unit (2013-2018)
  • Table 210. United Kingdom Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2013-2018)
  • Table 211. United Kingdom Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2013-2018)
  • Table 212. United Kingdom Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2013-2018)
  • Table 213. Netherlands Sickle Cell Anemia Drug Sales, by Type K Unit (2013-2018)
  • Table 214. Netherlands Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2013-2018)
  • Table 215. Netherlands Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2013-2018)
  • Table 216. Netherlands Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2013-2018)
  • Table 217. Rest of Europe Sickle Cell Anemia Drug Sales, by Type K Unit (2013-2018)
  • Table 218. Rest of Europe Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2013-2018)
  • Table 219. Rest of Europe Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2013-2018)
  • Table 220. Rest of Europe Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2013-2018)
  • Table 221. MEA Sickle Cell Anemia Drug Sales, by Country K Unit (2013-2018)
  • Table 222. MEA Sickle Cell Anemia Drug Sales, by Type K Unit (2013-2018)
  • Table 223. MEA Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2013-2018)
  • Table 224. MEA Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2013-2018)
  • Table 225. MEA Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2013-2018)
  • Table 226. Middle East Sickle Cell Anemia Drug Sales, by Type K Unit (2013-2018)
  • Table 227. Middle East Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2013-2018)
  • Table 228. Middle East Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2013-2018)
  • Table 229. Middle East Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2013-2018)
  • Table 230. Africa Sickle Cell Anemia Drug Sales, by Type K Unit (2013-2018)
  • Table 231. Africa Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2013-2018)
  • Table 232. Africa Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2013-2018)
  • Table 233. Africa Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2013-2018)
  • Table 234. North America Sickle Cell Anemia Drug Sales, by Country K Unit (2013-2018)
  • Table 235. North America Sickle Cell Anemia Drug Sales, by Type K Unit (2013-2018)
  • Table 236. North America Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2013-2018)
  • Table 237. North America Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2013-2018)
  • Table 238. North America Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2013-2018)
  • Table 239. United States Sickle Cell Anemia Drug Sales, by Type K Unit (2013-2018)
  • Table 240. United States Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2013-2018)
  • Table 241. United States Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2013-2018)
  • Table 242. United States Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2013-2018)
  • Table 243. Canada Sickle Cell Anemia Drug Sales, by Type K Unit (2013-2018)
  • Table 244. Canada Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2013-2018)
  • Table 245. Canada Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2013-2018)
  • Table 246. Canada Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2013-2018)
  • Table 247. Mexico Sickle Cell Anemia Drug Sales, by Type K Unit (2013-2018)
  • Table 248. Mexico Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2013-2018)
  • Table 249. Mexico Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2013-2018)
  • Table 250. Mexico Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2013-2018)
  • Table 251. Sickle Cell Anemia Drug: by Type(USD/Units)
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Sickle Cell Anemia Drug: by Type(USD Million)
  • Table 266. Sickle Cell Anemia Drug Antibiotics , by Region USD Million (2019-2024)
  • Table 267. Sickle Cell Anemia Drug Hydroxyurea , by Region USD Million (2019-2024)
  • Table 268. Sickle Cell Anemia Drug Pain-relieving medications , by Region USD Million (2019-2024)
  • Table 269. Sickle Cell Anemia Drug Others , by Region USD Million (2019-2024)
  • Table 270. Sickle Cell Anemia Drug: by Mode of Administration(USD Million)
  • Table 271. Sickle Cell Anemia Drug Oral , by Region USD Million (2019-2024)
  • Table 272. Sickle Cell Anemia Drug Intravenous , by Region USD Million (2019-2024)
  • Table 273. Sickle Cell Anemia Drug: by Disease Type(USD Million)
  • Table 274. Sickle Cell Anemia Drug Sickle cell anemia , by Region USD Million (2019-2024)
  • Table 275. Sickle Cell Anemia Drug Sickle beta thalassemia , by Region USD Million (2019-2024)
  • Table 276. Sickle Cell Anemia Drug Sickle hemoglobin c disease , by Region USD Million (2019-2024)
  • Table 277. Sickle Cell Anemia Drug: by Distribution Channel(USD Million)
  • Table 278. Sickle Cell Anemia Drug Retail pharmacies , by Region USD Million (2019-2024)
  • Table 279. Sickle Cell Anemia Drug Hospital pharmacies , by Region USD Million (2019-2024)
  • Table 280. Sickle Cell Anemia Drug Online pharmacies , by Region USD Million (2019-2024)
  • Table 281. South America Sickle Cell Anemia Drug, by Country USD Million (2019-2024)
  • Table 282. South America Sickle Cell Anemia Drug, by Type USD Million (2019-2024)
  • Table 283. South America Sickle Cell Anemia Drug, by Mode of Administration USD Million (2019-2024)
  • Table 284. South America Sickle Cell Anemia Drug, by Disease Type USD Million (2019-2024)
  • Table 285. South America Sickle Cell Anemia Drug, by Distribution Channel USD Million (2019-2024)
  • Table 286. Brazil Sickle Cell Anemia Drug, by Type USD Million (2019-2024)
  • Table 287. Brazil Sickle Cell Anemia Drug, by Mode of Administration USD Million (2019-2024)
  • Table 288. Brazil Sickle Cell Anemia Drug, by Disease Type USD Million (2019-2024)
  • Table 289. Brazil Sickle Cell Anemia Drug, by Distribution Channel USD Million (2019-2024)
  • Table 290. Argentina Sickle Cell Anemia Drug, by Type USD Million (2019-2024)
  • Table 291. Argentina Sickle Cell Anemia Drug, by Mode of Administration USD Million (2019-2024)
  • Table 292. Argentina Sickle Cell Anemia Drug, by Disease Type USD Million (2019-2024)
  • Table 293. Argentina Sickle Cell Anemia Drug, by Distribution Channel USD Million (2019-2024)
  • Table 294. Rest of South America Sickle Cell Anemia Drug, by Type USD Million (2019-2024)
  • Table 295. Rest of South America Sickle Cell Anemia Drug, by Mode of Administration USD Million (2019-2024)
  • Table 296. Rest of South America Sickle Cell Anemia Drug, by Disease Type USD Million (2019-2024)
  • Table 297. Rest of South America Sickle Cell Anemia Drug, by Distribution Channel USD Million (2019-2024)
  • Table 298. Asia Pacific Sickle Cell Anemia Drug, by Country USD Million (2019-2024)
  • Table 299. Asia Pacific Sickle Cell Anemia Drug, by Type USD Million (2019-2024)
  • Table 300. Asia Pacific Sickle Cell Anemia Drug, by Mode of Administration USD Million (2019-2024)
  • Table 301. Asia Pacific Sickle Cell Anemia Drug, by Disease Type USD Million (2019-2024)
  • Table 302. Asia Pacific Sickle Cell Anemia Drug, by Distribution Channel USD Million (2019-2024)
  • Table 303. China Sickle Cell Anemia Drug, by Type USD Million (2019-2024)
  • Table 304. China Sickle Cell Anemia Drug, by Mode of Administration USD Million (2019-2024)
  • Table 305. China Sickle Cell Anemia Drug, by Disease Type USD Million (2019-2024)
  • Table 306. China Sickle Cell Anemia Drug, by Distribution Channel USD Million (2019-2024)
  • Table 307. Japan Sickle Cell Anemia Drug, by Type USD Million (2019-2024)
  • Table 308. Japan Sickle Cell Anemia Drug, by Mode of Administration USD Million (2019-2024)
  • Table 309. Japan Sickle Cell Anemia Drug, by Disease Type USD Million (2019-2024)
  • Table 310. Japan Sickle Cell Anemia Drug, by Distribution Channel USD Million (2019-2024)
  • Table 311. India Sickle Cell Anemia Drug, by Type USD Million (2019-2024)
  • Table 312. India Sickle Cell Anemia Drug, by Mode of Administration USD Million (2019-2024)
  • Table 313. India Sickle Cell Anemia Drug, by Disease Type USD Million (2019-2024)
  • Table 314. India Sickle Cell Anemia Drug, by Distribution Channel USD Million (2019-2024)
  • Table 315. South Korea Sickle Cell Anemia Drug, by Type USD Million (2019-2024)
  • Table 316. South Korea Sickle Cell Anemia Drug, by Mode of Administration USD Million (2019-2024)
  • Table 317. South Korea Sickle Cell Anemia Drug, by Disease Type USD Million (2019-2024)
  • Table 318. South Korea Sickle Cell Anemia Drug, by Distribution Channel USD Million (2019-2024)
  • Table 319. Taiwan Sickle Cell Anemia Drug, by Type USD Million (2019-2024)
  • Table 320. Taiwan Sickle Cell Anemia Drug, by Mode of Administration USD Million (2019-2024)
  • Table 321. Taiwan Sickle Cell Anemia Drug, by Disease Type USD Million (2019-2024)
  • Table 322. Taiwan Sickle Cell Anemia Drug, by Distribution Channel USD Million (2019-2024)
  • Table 323. Australia Sickle Cell Anemia Drug, by Type USD Million (2019-2024)
  • Table 324. Australia Sickle Cell Anemia Drug, by Mode of Administration USD Million (2019-2024)
  • Table 325. Australia Sickle Cell Anemia Drug, by Disease Type USD Million (2019-2024)
  • Table 326. Australia Sickle Cell Anemia Drug, by Distribution Channel USD Million (2019-2024)
  • Table 327. Rest of Asia-Pacific Sickle Cell Anemia Drug, by Type USD Million (2019-2024)
  • Table 328. Rest of Asia-Pacific Sickle Cell Anemia Drug, by Mode of Administration USD Million (2019-2024)
  • Table 329. Rest of Asia-Pacific Sickle Cell Anemia Drug, by Disease Type USD Million (2019-2024)
  • Table 330. Rest of Asia-Pacific Sickle Cell Anemia Drug, by Distribution Channel USD Million (2019-2024)
  • Table 331. Europe Sickle Cell Anemia Drug, by Country USD Million (2019-2024)
  • Table 332. Europe Sickle Cell Anemia Drug, by Type USD Million (2019-2024)
  • Table 333. Europe Sickle Cell Anemia Drug, by Mode of Administration USD Million (2019-2024)
  • Table 334. Europe Sickle Cell Anemia Drug, by Disease Type USD Million (2019-2024)
  • Table 335. Europe Sickle Cell Anemia Drug, by Distribution Channel USD Million (2019-2024)
  • Table 336. Germany Sickle Cell Anemia Drug, by Type USD Million (2019-2024)
  • Table 337. Germany Sickle Cell Anemia Drug, by Mode of Administration USD Million (2019-2024)
  • Table 338. Germany Sickle Cell Anemia Drug, by Disease Type USD Million (2019-2024)
  • Table 339. Germany Sickle Cell Anemia Drug, by Distribution Channel USD Million (2019-2024)
  • Table 340. France Sickle Cell Anemia Drug, by Type USD Million (2019-2024)
  • Table 341. France Sickle Cell Anemia Drug, by Mode of Administration USD Million (2019-2024)
  • Table 342. France Sickle Cell Anemia Drug, by Disease Type USD Million (2019-2024)
  • Table 343. France Sickle Cell Anemia Drug, by Distribution Channel USD Million (2019-2024)
  • Table 344. Italy Sickle Cell Anemia Drug, by Type USD Million (2019-2024)
  • Table 345. Italy Sickle Cell Anemia Drug, by Mode of Administration USD Million (2019-2024)
  • Table 346. Italy Sickle Cell Anemia Drug, by Disease Type USD Million (2019-2024)
  • Table 347. Italy Sickle Cell Anemia Drug, by Distribution Channel USD Million (2019-2024)
  • Table 348. United Kingdom Sickle Cell Anemia Drug, by Type USD Million (2019-2024)
  • Table 349. United Kingdom Sickle Cell Anemia Drug, by Mode of Administration USD Million (2019-2024)
  • Table 350. United Kingdom Sickle Cell Anemia Drug, by Disease Type USD Million (2019-2024)
  • Table 351. United Kingdom Sickle Cell Anemia Drug, by Distribution Channel USD Million (2019-2024)
  • Table 352. Netherlands Sickle Cell Anemia Drug, by Type USD Million (2019-2024)
  • Table 353. Netherlands Sickle Cell Anemia Drug, by Mode of Administration USD Million (2019-2024)
  • Table 354. Netherlands Sickle Cell Anemia Drug, by Disease Type USD Million (2019-2024)
  • Table 355. Netherlands Sickle Cell Anemia Drug, by Distribution Channel USD Million (2019-2024)
  • Table 356. Rest of Europe Sickle Cell Anemia Drug, by Type USD Million (2019-2024)
  • Table 357. Rest of Europe Sickle Cell Anemia Drug, by Mode of Administration USD Million (2019-2024)
  • Table 358. Rest of Europe Sickle Cell Anemia Drug, by Disease Type USD Million (2019-2024)
  • Table 359. Rest of Europe Sickle Cell Anemia Drug, by Distribution Channel USD Million (2019-2024)
  • Table 360. MEA Sickle Cell Anemia Drug, by Country USD Million (2019-2024)
  • Table 361. MEA Sickle Cell Anemia Drug, by Type USD Million (2019-2024)
  • Table 362. MEA Sickle Cell Anemia Drug, by Mode of Administration USD Million (2019-2024)
  • Table 363. MEA Sickle Cell Anemia Drug, by Disease Type USD Million (2019-2024)
  • Table 364. MEA Sickle Cell Anemia Drug, by Distribution Channel USD Million (2019-2024)
  • Table 365. Middle East Sickle Cell Anemia Drug, by Type USD Million (2019-2024)
  • Table 366. Middle East Sickle Cell Anemia Drug, by Mode of Administration USD Million (2019-2024)
  • Table 367. Middle East Sickle Cell Anemia Drug, by Disease Type USD Million (2019-2024)
  • Table 368. Middle East Sickle Cell Anemia Drug, by Distribution Channel USD Million (2019-2024)
  • Table 369. Africa Sickle Cell Anemia Drug, by Type USD Million (2019-2024)
  • Table 370. Africa Sickle Cell Anemia Drug, by Mode of Administration USD Million (2019-2024)
  • Table 371. Africa Sickle Cell Anemia Drug, by Disease Type USD Million (2019-2024)
  • Table 372. Africa Sickle Cell Anemia Drug, by Distribution Channel USD Million (2019-2024)
  • Table 373. North America Sickle Cell Anemia Drug, by Country USD Million (2019-2024)
  • Table 374. North America Sickle Cell Anemia Drug, by Type USD Million (2019-2024)
  • Table 375. North America Sickle Cell Anemia Drug, by Mode of Administration USD Million (2019-2024)
  • Table 376. North America Sickle Cell Anemia Drug, by Disease Type USD Million (2019-2024)
  • Table 377. North America Sickle Cell Anemia Drug, by Distribution Channel USD Million (2019-2024)
  • Table 378. United States Sickle Cell Anemia Drug, by Type USD Million (2019-2024)
  • Table 379. United States Sickle Cell Anemia Drug, by Mode of Administration USD Million (2019-2024)
  • Table 380. United States Sickle Cell Anemia Drug, by Disease Type USD Million (2019-2024)
  • Table 381. United States Sickle Cell Anemia Drug, by Distribution Channel USD Million (2019-2024)
  • Table 382. Canada Sickle Cell Anemia Drug, by Type USD Million (2019-2024)
  • Table 383. Canada Sickle Cell Anemia Drug, by Mode of Administration USD Million (2019-2024)
  • Table 384. Canada Sickle Cell Anemia Drug, by Disease Type USD Million (2019-2024)
  • Table 385. Canada Sickle Cell Anemia Drug, by Distribution Channel USD Million (2019-2024)
  • Table 386. Mexico Sickle Cell Anemia Drug, by Type USD Million (2019-2024)
  • Table 387. Mexico Sickle Cell Anemia Drug, by Mode of Administration USD Million (2019-2024)
  • Table 388. Mexico Sickle Cell Anemia Drug, by Disease Type USD Million (2019-2024)
  • Table 389. Mexico Sickle Cell Anemia Drug, by Distribution Channel USD Million (2019-2024)
  • Table 390. Sickle Cell Anemia Drug Sales: by Type(K Unit)
  • Table 391. Sickle Cell Anemia Drug Sales Antibiotics , by Region K Unit (2019-2024)
  • Table 392. Sickle Cell Anemia Drug Sales Hydroxyurea , by Region K Unit (2019-2024)
  • Table 393. Sickle Cell Anemia Drug Sales Pain-relieving medications , by Region K Unit (2019-2024)
  • Table 394. Sickle Cell Anemia Drug Sales Others , by Region K Unit (2019-2024)
  • Table 395. Sickle Cell Anemia Drug Sales: by Mode of Administration(K Unit)
  • Table 396. Sickle Cell Anemia Drug Sales Oral , by Region K Unit (2019-2024)
  • Table 397. Sickle Cell Anemia Drug Sales Intravenous , by Region K Unit (2019-2024)
  • Table 398. Sickle Cell Anemia Drug Sales: by Disease Type(K Unit)
  • Table 399. Sickle Cell Anemia Drug Sales Sickle cell anemia , by Region K Unit (2019-2024)
  • Table 400. Sickle Cell Anemia Drug Sales Sickle beta thalassemia , by Region K Unit (2019-2024)
  • Table 401. Sickle Cell Anemia Drug Sales Sickle hemoglobin c disease , by Region K Unit (2019-2024)
  • Table 402. Sickle Cell Anemia Drug Sales: by Distribution Channel(K Unit)
  • Table 403. Sickle Cell Anemia Drug Sales Retail pharmacies , by Region K Unit (2019-2024)
  • Table 404. Sickle Cell Anemia Drug Sales Hospital pharmacies , by Region K Unit (2019-2024)
  • Table 405. Sickle Cell Anemia Drug Sales Online pharmacies , by Region K Unit (2019-2024)
  • Table 406. South America Sickle Cell Anemia Drug Sales, by Country K Unit (2019-2024)
  • Table 407. South America Sickle Cell Anemia Drug Sales, by Type K Unit (2019-2024)
  • Table 408. South America Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2019-2024)
  • Table 409. South America Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2019-2024)
  • Table 410. South America Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2019-2024)
  • Table 411. Brazil Sickle Cell Anemia Drug Sales, by Type K Unit (2019-2024)
  • Table 412. Brazil Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2019-2024)
  • Table 413. Brazil Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2019-2024)
  • Table 414. Brazil Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2019-2024)
  • Table 415. Argentina Sickle Cell Anemia Drug Sales, by Type K Unit (2019-2024)
  • Table 416. Argentina Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2019-2024)
  • Table 417. Argentina Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2019-2024)
  • Table 418. Argentina Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2019-2024)
  • Table 419. Rest of South America Sickle Cell Anemia Drug Sales, by Type K Unit (2019-2024)
  • Table 420. Rest of South America Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2019-2024)
  • Table 421. Rest of South America Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2019-2024)
  • Table 422. Rest of South America Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2019-2024)
  • Table 423. Asia Pacific Sickle Cell Anemia Drug Sales, by Country K Unit (2019-2024)
  • Table 424. Asia Pacific Sickle Cell Anemia Drug Sales, by Type K Unit (2019-2024)
  • Table 425. Asia Pacific Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2019-2024)
  • Table 426. Asia Pacific Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2019-2024)
  • Table 427. Asia Pacific Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2019-2024)
  • Table 428. China Sickle Cell Anemia Drug Sales, by Type K Unit (2019-2024)
  • Table 429. China Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2019-2024)
  • Table 430. China Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2019-2024)
  • Table 431. China Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2019-2024)
  • Table 432. Japan Sickle Cell Anemia Drug Sales, by Type K Unit (2019-2024)
  • Table 433. Japan Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2019-2024)
  • Table 434. Japan Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2019-2024)
  • Table 435. Japan Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2019-2024)
  • Table 436. India Sickle Cell Anemia Drug Sales, by Type K Unit (2019-2024)
  • Table 437. India Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2019-2024)
  • Table 438. India Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2019-2024)
  • Table 439. India Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2019-2024)
  • Table 440. South Korea Sickle Cell Anemia Drug Sales, by Type K Unit (2019-2024)
  • Table 441. South Korea Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2019-2024)
  • Table 442. South Korea Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2019-2024)
  • Table 443. South Korea Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2019-2024)
  • Table 444. Taiwan Sickle Cell Anemia Drug Sales, by Type K Unit (2019-2024)
  • Table 445. Taiwan Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2019-2024)
  • Table 446. Taiwan Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2019-2024)
  • Table 447. Taiwan Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2019-2024)
  • Table 448. Australia Sickle Cell Anemia Drug Sales, by Type K Unit (2019-2024)
  • Table 449. Australia Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2019-2024)
  • Table 450. Australia Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2019-2024)
  • Table 451. Australia Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2019-2024)
  • Table 452. Rest of Asia-Pacific Sickle Cell Anemia Drug Sales, by Type K Unit (2019-2024)
  • Table 453. Rest of Asia-Pacific Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2019-2024)
  • Table 454. Rest of Asia-Pacific Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2019-2024)
  • Table 455. Rest of Asia-Pacific Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2019-2024)
  • Table 456. Europe Sickle Cell Anemia Drug Sales, by Country K Unit (2019-2024)
  • Table 457. Europe Sickle Cell Anemia Drug Sales, by Type K Unit (2019-2024)
  • Table 458. Europe Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2019-2024)
  • Table 459. Europe Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2019-2024)
  • Table 460. Europe Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2019-2024)
  • Table 461. Germany Sickle Cell Anemia Drug Sales, by Type K Unit (2019-2024)
  • Table 462. Germany Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2019-2024)
  • Table 463. Germany Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2019-2024)
  • Table 464. Germany Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2019-2024)
  • Table 465. France Sickle Cell Anemia Drug Sales, by Type K Unit (2019-2024)
  • Table 466. France Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2019-2024)
  • Table 467. France Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2019-2024)
  • Table 468. France Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2019-2024)
  • Table 469. Italy Sickle Cell Anemia Drug Sales, by Type K Unit (2019-2024)
  • Table 470. Italy Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2019-2024)
  • Table 471. Italy Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2019-2024)
  • Table 472. Italy Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2019-2024)
  • Table 473. United Kingdom Sickle Cell Anemia Drug Sales, by Type K Unit (2019-2024)
  • Table 474. United Kingdom Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2019-2024)
  • Table 475. United Kingdom Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2019-2024)
  • Table 476. United Kingdom Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2019-2024)
  • Table 477. Netherlands Sickle Cell Anemia Drug Sales, by Type K Unit (2019-2024)
  • Table 478. Netherlands Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2019-2024)
  • Table 479. Netherlands Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2019-2024)
  • Table 480. Netherlands Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2019-2024)
  • Table 481. Rest of Europe Sickle Cell Anemia Drug Sales, by Type K Unit (2019-2024)
  • Table 482. Rest of Europe Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2019-2024)
  • Table 483. Rest of Europe Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2019-2024)
  • Table 484. Rest of Europe Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2019-2024)
  • Table 485. MEA Sickle Cell Anemia Drug Sales, by Country K Unit (2019-2024)
  • Table 486. MEA Sickle Cell Anemia Drug Sales, by Type K Unit (2019-2024)
  • Table 487. MEA Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2019-2024)
  • Table 488. MEA Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2019-2024)
  • Table 489. MEA Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2019-2024)
  • Table 490. Middle East Sickle Cell Anemia Drug Sales, by Type K Unit (2019-2024)
  • Table 491. Middle East Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2019-2024)
  • Table 492. Middle East Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2019-2024)
  • Table 493. Middle East Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2019-2024)
  • Table 494. Africa Sickle Cell Anemia Drug Sales, by Type K Unit (2019-2024)
  • Table 495. Africa Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2019-2024)
  • Table 496. Africa Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2019-2024)
  • Table 497. Africa Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2019-2024)
  • Table 498. North America Sickle Cell Anemia Drug Sales, by Country K Unit (2019-2024)
  • Table 499. North America Sickle Cell Anemia Drug Sales, by Type K Unit (2019-2024)
  • Table 500. North America Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2019-2024)
  • Table 501. North America Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2019-2024)
  • Table 502. North America Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2019-2024)
  • Table 503. United States Sickle Cell Anemia Drug Sales, by Type K Unit (2019-2024)
  • Table 504. United States Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2019-2024)
  • Table 505. United States Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2019-2024)
  • Table 506. United States Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2019-2024)
  • Table 507. Canada Sickle Cell Anemia Drug Sales, by Type K Unit (2019-2024)
  • Table 508. Canada Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2019-2024)
  • Table 509. Canada Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2019-2024)
  • Table 510. Canada Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2019-2024)
  • Table 511. Mexico Sickle Cell Anemia Drug Sales, by Type K Unit (2019-2024)
  • Table 512. Mexico Sickle Cell Anemia Drug Sales, by Mode of Administration K Unit (2019-2024)
  • Table 513. Mexico Sickle Cell Anemia Drug Sales, by Disease Type K Unit (2019-2024)
  • Table 514. Mexico Sickle Cell Anemia Drug Sales, by Distribution Channel K Unit (2019-2024)
  • Table 515. Sickle Cell Anemia Drug: by Type(USD/Units)
  • Table 516. Research Programs/Design for This Report
  • Table 517. Key Data Information from Secondary Sources
  • Table 518. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Sickle Cell Anemia Drug: by Type USD Million (2013-2018)
  • Figure 5. Global Sickle Cell Anemia Drug: by Mode of Administration USD Million (2013-2018)
  • Figure 6. Global Sickle Cell Anemia Drug: by Disease Type USD Million (2013-2018)
  • Figure 7. Global Sickle Cell Anemia Drug: by Distribution Channel USD Million (2013-2018)
  • Figure 8. South America Sickle Cell Anemia Drug Share (%), by Country
  • Figure 9. Asia Pacific Sickle Cell Anemia Drug Share (%), by Country
  • Figure 10. Europe Sickle Cell Anemia Drug Share (%), by Country
  • Figure 11. MEA Sickle Cell Anemia Drug Share (%), by Country
  • Figure 12. North America Sickle Cell Anemia Drug Share (%), by Country
  • Figure 13. Global Sickle Cell Anemia Drug: by Type K Unit (2013-2018)
  • Figure 14. Global Sickle Cell Anemia Drug: by Mode of Administration K Unit (2013-2018)
  • Figure 15. Global Sickle Cell Anemia Drug: by Disease Type K Unit (2013-2018)
  • Figure 16. Global Sickle Cell Anemia Drug: by Distribution Channel K Unit (2013-2018)
  • Figure 17. South America Sickle Cell Anemia Drug Share (%), by Country
  • Figure 18. Asia Pacific Sickle Cell Anemia Drug Share (%), by Country
  • Figure 19. Europe Sickle Cell Anemia Drug Share (%), by Country
  • Figure 20. MEA Sickle Cell Anemia Drug Share (%), by Country
  • Figure 21. North America Sickle Cell Anemia Drug Share (%), by Country
  • Figure 22. Global Sickle Cell Anemia Drug: by Type USD/Units (2013-2018)
  • Figure 23. Global Sickle Cell Anemia Drug share by Players 2018 (%)
  • Figure 24. Global Sickle Cell Anemia Drug share by Players (Top 3) 2018(%)
  • Figure 25. Global Sickle Cell Anemia Drug share by Players (Top 5) 2018(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Alnylam Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Alnylam Pharmaceuticals, Inc. (United States) Revenue: by Geography 2018
  • Figure 29. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Pfizer Inc. (United States) Revenue: by Geography 2018
  • Figure 31. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Novartis AG (Switzerland) Revenue: by Geography 2018
  • Figure 33. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 34. Eli Lilly and Company (United States) Revenue: by Geography 2018
  • Figure 35. AstraZeneca Plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 36. AstraZeneca Plc. (United Kingdom) Revenue: by Geography 2018
  • Figure 37. Baxter International Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Baxter International Inc. (United States) Revenue: by Geography 2018
  • Figure 39. Emmaus Life Sciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Emmaus Life Sciences, Inc. (United States) Revenue: by Geography 2018
  • Figure 41. Sangamo Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. Sangamo Therapeutics, Inc. (United States) Revenue: by Geography 2018
  • Figure 43. Bluebird bio, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. Bluebird bio, Inc. (United States) Revenue: by Geography 2018
  • Figure 45. Global Blood Therapeutics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 46. Global Blood Therapeutics Inc. (United States) Revenue: by Geography 2018
  • Figure 47. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 48. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2018
  • Figure 49. Acceleron Pharma, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 50. Acceleron Pharma, Inc. (United States) Revenue: by Geography 2018
  • Figure 51. Arena Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 52. Arena Pharmaceuticals, Inc. (United States) Revenue: by Geography 2018
  • Figure 53. Global Sickle Cell Anemia Drug: by Type USD Million (2019-2024)
  • Figure 54. Global Sickle Cell Anemia Drug: by Mode of Administration USD Million (2019-2024)
  • Figure 55. Global Sickle Cell Anemia Drug: by Disease Type USD Million (2019-2024)
  • Figure 56. Global Sickle Cell Anemia Drug: by Distribution Channel USD Million (2019-2024)
  • Figure 57. South America Sickle Cell Anemia Drug Share (%), by Country
  • Figure 58. Asia Pacific Sickle Cell Anemia Drug Share (%), by Country
  • Figure 59. Europe Sickle Cell Anemia Drug Share (%), by Country
  • Figure 60. MEA Sickle Cell Anemia Drug Share (%), by Country
  • Figure 61. North America Sickle Cell Anemia Drug Share (%), by Country
  • Figure 62. Global Sickle Cell Anemia Drug: by Type K Unit (2019-2024)
  • Figure 63. Global Sickle Cell Anemia Drug: by Mode of Administration K Unit (2019-2024)
  • Figure 64. Global Sickle Cell Anemia Drug: by Disease Type K Unit (2019-2024)
  • Figure 65. Global Sickle Cell Anemia Drug: by Distribution Channel K Unit (2019-2024)
  • Figure 66. South America Sickle Cell Anemia Drug Share (%), by Country
  • Figure 67. Asia Pacific Sickle Cell Anemia Drug Share (%), by Country
  • Figure 68. Europe Sickle Cell Anemia Drug Share (%), by Country
  • Figure 69. MEA Sickle Cell Anemia Drug Share (%), by Country
  • Figure 70. North America Sickle Cell Anemia Drug Share (%), by Country
  • Figure 71. Global Sickle Cell Anemia Drug: by Type USD/Units (2019-2024)
List of companies from research coverage that are profiled in the study
  • Alnylam Pharmaceuticals, Inc. (United States)
  • Pfizer Inc. (United States)
  • Novartis AG (Switzerland)
  • Eli Lilly and Company (United States)
  • AstraZeneca Plc. (United Kingdom)
  • Baxter International Inc. (United States)
  • Emmaus Life Sciences, Inc. (United States)
  • Sangamo Therapeutics, Inc. (United States)
  • Bluebird bio, Inc. (United States)
  • Global Blood Therapeutics Inc. (United States)
  • Bristol-Myers Squibb Company (United States)
  • Acceleron Pharma, Inc. (United States)
  • Arena Pharmaceuticals, Inc. (United States)
Select User Access Type

Key Highlights of Report


Dec 2019 180 Pages 51 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Sickle Cell Anemia Drug Market Quantitative research analysis
Global Sickle Cell Anemia Drug Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Sickle Cell Anemia Drug Market Report?

Have a Query? Click Here

Other Related Reports

Multiple Sclerosis Comprehensive Study by Type (Clinically Isolated Syndrome, Relapsing-remitting, Secondary progressive, Primary progressive, Progressive-relapsing), Distribution Channel (Hospitals ...
$ 3800
Folinic Acid Comprehensive Study by Application (Hospitals, Pharmaceuticals, Nutraceutical, Food and Beverages, Others), Form (Tablets, Injection, Others), Distribution Channels (Online, Offline) Pla...
$ 3500
Ipecac Comprehensive Study by Type (Powder, Liquid (Syrup)), Application (Hospitals, Clinics), Distribution Channel (Online, Offline) Players and Region - Global Market Outlook to 2024
$ 3500
Kidney Detox Comprehensive Study by Type (Tablets, Capsules), Distribution Channel (Direct sales, Indirect sales), Industry Segmentation (Hospitals, Individuals) Players and Region - Global Market O...
$ 3500
Betaxolol Comprehensive Study by Form (Solution/Suspension, Film-Coated Tablets), Distribution Channels (Hospitals, Medical Pharmacy, Online Medical Store), Disease Indication (Glaucoma, Hypertension...
$ 3350
Citrus Bioflavonoids Comprehensive Study by Type (Conventional, Organic), Application (Pharmaceuticals & dietary supplements, Food & beverages, Animal feed, Cosmetics & Personal care), Products (Hesp...
$ 3650